
The FDA has granted accelerated approval for Seattle Genetics and Astellas Pharma’s bladder cancer drug Padcev (enfortumab vedotin-ejfv). The drug’s …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical

